Dr. Santosh Kumar Chellapuram
Senior Consultant – Medical Oncology, Haemato-oncology & BMT Specialist
9 Years of Experience
Rs. 800 Fees
Qualifications
- DM – Medical Oncology- Gold Medalist
All India Institute of Medical Sciences (AIIMS), New Delhi - MD – Internal Medicine
All India Institute of Medical Sciences (AIIMS), New Delhi - MBBS
Osmania Medical College, Hyderabad
Experience
- Consultant – Medical Oncology
Care Hospitals, Banjara Hills, Hyderabad - Consultant – Medical Oncology
Asvins Hospitals, Somajiguda, Hyderabad - Consultant – Medical Oncology
Mahavir Hospital, Masab Tank, Hyderabad
Field of Expertise
- Diagnosis and Treatment of Various Solid and Hematologic Cancers
- Advanced Immunotherapy and Targeted Therapy
- Bone Marrow Transplantation (Autologous & Allogenic)
- Preventive Oncology and Role of Genetics in Cancer
- Antibody Drug Conjugates (Payload-Linked Therapies)
- CAR T-Cell Therapy for Hematologic Malignancies
- Principal Investigator (PI) – International Clinical Trials
Research & Publications
Research, Publications & Clinical Trials
Key Publications
Key Publications
- Immune checkpoint inhibitors in advanced non–small cell lung cancer: A multicentric experience from India. Current Problems in Cancer, 2020.
- POEMS Syndrome: Single-centre study of 68 patients comparing ASCT vs. non-ASCT cohorts. Clinical Lymphoma Myeloma and Leukemia, 2019.
- Containing the COVID-19 spread in an oncology day care facility in India. IJMPO, 2020; 41(4): 468–470.
- Systemic therapy for breast cancer during the SARS-CoV-2 pandemic. Cancer Research, Statistics, and Treatment, 2020.
- Editorial on Dengue virus infection. NMJI, 2016; 29(2): 61–63.
- VRd vs. VCd as induction therapy for multiple myeloma: A Phase III randomized study. CLML, 2019.
- Primary Mediastinal B Cell Lymphoma: Institutional experience with DAEPOCH-R. Indian J Hematol Blood Transfus, 2020.
- Primary Amyloidosis: Experience from an Indian tertiary centre. CLML, 2019.
- Aprepitant in AML chemotherapy-induced emesis: BMJ Supportive & Palliative Care, 2020.
- Relapsed Myeloma after ASCT: 20-year outcomes. CLML, 2019.
- Renal impairment in Multiple Myeloma: Outcomes with novel induction and ASCT. Clinical Hematology Int., 2019.
- Ewing Sarcoma of Kidney with IVC Thrombus: Imaging Insights. Clinical Nuclear Medicine, 2019.
Book Chapters
- Cardiac Amyloidosis – CSI Cardiology Update 2018 (Co-authored with Dr. Lalit Kumar)
- Palliative Care in Breast Cancer – Oxford University Press, “Problem-Oriented Palliative Care” (In Press)
Clinical Trials & Investigational Roles
Principal Investigator in International Clinical Trials:
- EMERALD-3 Trial: Durvalumab + Tremelimumab ± Lenvatinib + TACE vs. TACE alone in HCC
- PACIFIC-8 Trial: Durvalumab + Domvanalimab in unresectable Stage III NSCLC
- ASIAD-3 Trial: CA-170 + chemotherapy in Stage IV NSCLC
- TEJAS-1 Trial: ODM-203 in FGFR3-mutant Urothelial Carcinoma
Certifications & Memberships
Awards & Recognitions
- Gold Medalist – DM Medical Oncology, AIIMS
- Best Orator – TYSA 2020 National Conference
- 1st Runner-up – TYSA 2020 National Conference
- Winner – ICON 2018 National Medical Oncology Quiz
- Poster Presentation – International Myeloma Conference (IMWG), Boston, 2019
- Winner – State and Regional Level Psychiatry Quiz, MBBS
- Pratibha Awards – For Academic Excellence in Intermediate (Class 11 & 12)
- Graduated with MBBS in First Class
Qualifications
- DM – Medical Oncology- Gold Medalist
All India Institute of Medical Sciences (AIIMS), New Delhi - MD – Internal Medicine
All India Institute of Medical Sciences (AIIMS), New Delhi - MBBS
Osmania Medical College, Hyderabad
Experience
- Consultant – Medical Oncology
Care Hospitals, Banjara Hills, Hyderabad - Consultant – Medical Oncology
Asvins Hospitals, Somajiguda, Hyderabad - Consultant – Medical Oncology
Mahavir Hospital, Masab Tank, Hyderabad
Field of Expertise
- Diagnosis and Treatment of Various Solid and Hematologic Cancers
- Advanced Immunotherapy and Targeted Therapy
- Bone Marrow Transplantation (Autologous & Allogenic)
- Preventive Oncology and Role of Genetics in Cancer
- Antibody Drug Conjugates (Payload-Linked Therapies)
- CAR T-Cell Therapy for Hematologic Malignancies
- Principal Investigator (PI) – International Clinical Trials
Research & Publications
Research, Publications & Clinical Trials
Key Publications
Key Publications
- Immune checkpoint inhibitors in advanced non–small cell lung cancer: A multicentric experience from India. Current Problems in Cancer, 2020.
- POEMS Syndrome: Single-centre study of 68 patients comparing ASCT vs. non-ASCT cohorts. Clinical Lymphoma Myeloma and Leukemia, 2019.
- Containing the COVID-19 spread in an oncology day care facility in India. IJMPO, 2020; 41(4): 468–470.
- Systemic therapy for breast cancer during the SARS-CoV-2 pandemic. Cancer Research, Statistics, and Treatment, 2020.
- Editorial on Dengue virus infection. NMJI, 2016; 29(2): 61–63.
- VRd vs. VCd as induction therapy for multiple myeloma: A Phase III randomized study. CLML, 2019.
- Primary Mediastinal B Cell Lymphoma: Institutional experience with DAEPOCH-R. Indian J Hematol Blood Transfus, 2020.
- Primary Amyloidosis: Experience from an Indian tertiary centre. CLML, 2019.
- Aprepitant in AML chemotherapy-induced emesis: BMJ Supportive & Palliative Care, 2020.
- Relapsed Myeloma after ASCT: 20-year outcomes. CLML, 2019.
- Renal impairment in Multiple Myeloma: Outcomes with novel induction and ASCT. Clinical Hematology Int., 2019.
- Ewing Sarcoma of Kidney with IVC Thrombus: Imaging Insights. Clinical Nuclear Medicine, 2019.
Book Chapters
- Cardiac Amyloidosis – CSI Cardiology Update 2018 (Co-authored with Dr. Lalit Kumar)
- Palliative Care in Breast Cancer – Oxford University Press, “Problem-Oriented Palliative Care” (In Press)
Clinical Trials & Investigational Roles
Principal Investigator in International Clinical Trials:
- EMERALD-3 Trial: Durvalumab + Tremelimumab ± Lenvatinib + TACE vs. TACE alone in HCC
- PACIFIC-8 Trial: Durvalumab + Domvanalimab in unresectable Stage III NSCLC
- ASIAD-3 Trial: CA-170 + chemotherapy in Stage IV NSCLC
- TEJAS-1 Trial: ODM-203 in FGFR3-mutant Urothelial Carcinoma
Certifications & Memberships
Awards & Recognitions
- Gold Medalist – DM Medical Oncology, AIIMS
- Best Orator – TYSA 2020 National Conference
- 1st Runner-up – TYSA 2020 National Conference
- Winner – ICON 2018 National Medical Oncology Quiz
- Poster Presentation – International Myeloma Conference (IMWG), Boston, 2019
- Winner – State and Regional Level Psychiatry Quiz, MBBS
- Pratibha Awards – For Academic Excellence in Intermediate (Class 11 & 12)
- Graduated with MBBS in First Class
